Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5’ splice site: Generation of etoposide resistance in human leukemia K562 cells

PLoS ONE(2022)10.1371/journal.pone.0265794Source: DataRank Database

Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5’ splice site: Generation of etoposide resistance in human leukemia K562 cells is a research paper published in PLoS ONE (2022). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

geo

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.39)OA: goldTopics (47)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Jessika Carvajal‐Moreno,Xinyi Wang ORCID,Maciej Pietrzak ORCID,Jack C. Yalowich ORCID,Terry S. Elton ORCID

Live enrichment

PubMed:35617303 PMC:PMC9135202 OpenAlex:https://openalex.org/W4281638376

National Cancer Institute

Grant: R01 CA226906-01A1

NCI NIH HHS

Grant: R01 CA226906

National Institutes of Health

Grant: 5R01CA226906-05

Novel Topoisomerase II alpha isoform as a drug resistance determinant

FWCI

0.39

Citation Percentile

0.5%

Citation Trend

2022

2023

2024

goldLicense: cc-by

journalhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0265794&type=printable

publisherhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0265794&type=printable

publisherhttps://dx.plos.org/10.1371/journal.pone.0265794

journalhttps://doi.org/10.1371/journal.pone.0265794

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35617303

Fields of Study

Cancer therapeutics and mechanismsAdvanced biosensing and bioanalysis techniquesLung Cancer Research Studies0301 basic medicine0303 health sciences03 medical and health sciencesAntigens, NeoplasmCRISPR-Cas SystemsDNA Topoisomerases, Type IIEtoposideHumansIntronsK562 CellsLeukemiaRNA Splice SitesRNA, Messenger

MeSH Terms

Antigens, NeoplasmDNA Topoisomerases, Type IIEtoposideHumansIntronsLeukemiaRNA, MessengerK562 CellsRNA Splice SitesCRISPR-Cas Systems

Keywords

BiologyMolecular biologyIntronExonEtoposideGeneGeneticsLeukemiaScienceQRIntronsDNA Topoisomerases, Type IIAntigens, NeoplasmMedicineHumansRNA Splice SitesRNA, MessengerCRISPR-Cas SystemsK562 CellsResearch Article

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5’ splice site: Generation of etoposide resistance in human leukemia K562 cells

FAIR Checklist

Authors (6)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)